Neoplasms, Glandular and Epithelial  >>  Cilcane (cilengitide)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cilcane (cilengitide) / Iceni Pharma
NCT01044225 / 2009-012324-83: Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma

Terminated
2
12
Europe
Cetuximab, Cilengitide EMD 121974
Bart Neyns
Glioblastoma
09/11
09/11
CORE, NCT00813943: Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

Completed
2
265
US, Europe
Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
EMD Serono, Merck KGaA, Darmstadt, Germany
Glioblastoma
02/13
08/13

Download Options